nach oben

19.05.2024 | Research

Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018

verfasst von: Yuxiao Zhang, Min Zhang, Shanjiamei Jiang, Heng Hu, Xinzhi Wang, Fan Yu, Yue’e Huang, Yali Liang

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study investigated the potential effects of perfluoroalkyl substance (PFAS) in serum on MAFLD, NAFLD, and liver fibrosis.

Methods

Our sample included 696 participants (≥ 18 years) from the 2017–2018 NHANES study with available serum PFASs, covariates, and outcomes. Using the first quartile of PFAS as the reference group, we used weighted binary logistic regression and multiple ordered logistic regression used to analyze the relationship between PFAS and MAFLD, NAFLD, and liver fibrosis and multiple ordinal logistic regression to investigate the relationship between PFAS and MAFLD, NAFLD, and liver fibrosis and calculated the odds ratio (OR) and 95% confidence interval for each chemical. Finally, stratified analysis and sensitivity analysis were performed according to gender, age, BMI, and serum cotinine concentration.

Results

A total of 696 study subjects were included, including 212 NAFLD patients (weighted 27.03%) and 253 MAFLD patients (weighted 32.65%). The quartile 2 of serum PFOA was positively correlated with MAFLD and NAFLD (MAFLD, OR 2.29, 95% CI 1.05–4.98; NAFLD, OR 2.37, 95% CI 1.03–5.47). PFAS were not significantly associated with liver fibrosis after adjusting for potential confounders in MAFLD and NAFLD. Stratified analysis showed that PFOA was strongly associated with MAFLD, NAFLD, and liver fibrosis in males and obese subjects. In women over 60 years old, PFHxS was also correlated with MAFLD, NAFLD, and liver fibrosis.

Conclusion

The serum PFOA was positively associated with MAFLD and NAFLD in US adults. After stratified analysis, the serum PFHxS was correlated with MFALD, NAFLD, and liver fibrosis.

Nur mit Berechtigung zugänglich

Young AS, Sparer-Fine EH, Pickard HM, Sunderland EM, Peaslee GF, Allen JG (2021) Per- and polyfluoroalkyl substances (PFAS) and total fluorine in fire station dust. J Expo Sci Environ Epidemiol 31:930–942. https://doi.org/10.1038/s41370-021-00288-7CrossRefPubMedPubMedCentral

Chiu WA, Lynch MT, Lay CR et al (2022) Bayesian estimation of human population toxicokinetics of PFOA, PFOS, PFHxS, and PFNA from studies of contaminated drinking water. Environ Health Perspect 130:127001. https://doi.org/10.1289/ehp10103CrossRefPubMedPubMedCentral

Costello E, Rock S, Stratakis N et al (2022) Exposure to per-and polyfluoroalkyl substances and markers of liver injury: a systematic review and meta-analysis. Environ Health Perspect 130:46001. https://doi.org/10.1289/ehp10092CrossRefPubMed

Kannan K, Corsolini S, Falandysz J et al (2004) Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 38:4489–4495. https://doi.org/10.1021/es0493446CrossRefPubMed

Graber JM, Black TM, Shah NN et al (2021) Prevalence and predictors of per-and polyfluoroalkyl substances (PFAS) serum levels among members of a suburban US volunteer fire department. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph18073730CrossRefPubMedPubMedCentral

Cao Y, Ng C (2021) Absorption, distribution, and toxicity of per-and polyfluoroalkyl substances (PFAS) in the brain: a review. Environ Sci Process Impacts 23:1623–1640. https://doi.org/10.1039/d1em00228gCrossRefPubMed

Fenton SE, Ducatman A, Boobis A et al (2021) Per-and polyfluoroalkyl substance toxicity and human health review: current state of knowledge and strategies for informing future research. Environ Toxicol Chem 40:606–630. https://doi.org/10.1002/etc.4890CrossRefPubMed

Jane LEL, Yamada M, Ford J, Owens G, Prow T, Juhasz A (2022) Health-related toxicity of emerging per-and polyfluoroalkyl substances: comparison to legacy PFOS and PFOA. Environ Res 212:113431. https://doi.org/10.1016/j.envres.2022.113431CrossRef

Aghaei Z, Steeves KL, Jobst KJ, Cahill LS (2022) The impact of perfluoroalkyl substances on pregnancy, birth outcomes, and offspring development: a review of data from mouse models†. Biol Reprod 106:397–407. https://doi.org/10.1093/biolre/ioab223CrossRefPubMed

10.

Ding T, Yan W, Zhou T et al (2022) Endocrine disrupting chemicals impact on ovarian aging: evidence from epidemiological and experimental evidence. Environ Pollut 305:119269. https://doi.org/10.1016/j.envpol.2022.119269CrossRefPubMed

11.

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908–922. https://doi.org/10.1038/s41591-018-0104-9CrossRefPubMedPubMedCentral

12.

Huang DQ, El-Serag HB, Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223–238. https://doi.org/10.1038/s41575-020-00381-6CrossRefPubMed

13.

Nan Y, An J, Bao J et al (2021) The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 75:454–461. https://doi.org/10.1016/j.jhep.2021.05.003CrossRefPubMed

14.

Lin S, Huang J, Wang M et al (2020) Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver international: off J Int Assoc Study Liver 40:2082–2089. https://doi.org/10.1111/liv.14548CrossRef

15.

Eslam M, Ratziu V, George J (2021) Yet more evidence that MAFLD is more than a name change. J Hepatol 74:977–979. https://doi.org/10.1016/j.jhep.2020.12.025CrossRefPubMed

16.

Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202–209. https://doi.org/10.1016/j.jhep.2020.03.039CrossRefPubMed

17.

Gofton C, Upendran Y, Zheng MH, George J (2023) MAFLD: how is it different from NAFLD? Clin Mol Hepatol 29:S17-s31. https://doi.org/10.3350/cmh.2022.0367CrossRefPubMed

18.

Cai J, Zhang XJ, Li H (2019) Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev 39:328–348. https://doi.org/10.1002/med.21515CrossRefPubMed

19.

Myers S, Neyroud-Caspar I, Spahr L et al (2021) NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep: Innov Hepatol 3:100231. https://doi.org/10.1016/j.jhepr.2021.100231CrossRef

20.

Zhao Y, Li H (2022) Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease. Scand J Gastroenterol 57:872–877. https://doi.org/10.1080/00365521.2022.2041085CrossRefPubMed

21.

Sen P, Qadri S, Luukkonen PK et al (2022) Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. J Hepatol 76:283–293. https://doi.org/10.1016/j.jhep.2021.09.039CrossRefPubMed

22.

Liu JJ, Cui XX, Tan YW et al (2022) Per- and perfluoroalkyl substances alternatives, mixtures and liver function in adults: a community-based population study in China. Environ Int 163:107179. https://doi.org/10.1016/j.envint.2022.107179CrossRefPubMed

23.

Jain RB, Ducatman A (2019) Selective associations of recent low concentrations of perfluoroalkyl substances with liver function biomarkers: NHANES 2011 to 2014 data on US adults aged ≥20 years. J Occup Environ Med 61:293–302. https://doi.org/10.1097/jom.0000000000001532CrossRefPubMed

24.

Wu X, Xie G, Xu X, Wu W, Yang B (2018) Adverse bioeffect of perfluorooctanoic acid on liver metabolic function in mice. Environ Sci Pollut Res Int 25:4787–4793. https://doi.org/10.1007/s11356-017-0872-7CrossRefPubMed

25.

Goodrich JA, Walker D, Lin X et al (2022) Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort. JHEP Rep 4:100550. https://doi.org/10.1016/j.jhepr.2022.100550CrossRefPubMedPubMedCentral

26.

Jin R, McConnell R, Catherine C et al (2020) Perfluoroalkyl substances and severity of nonalcoholic fatty liver in children: an untargeted metabolomics approach. Environ Int 134:105220. https://doi.org/10.1016/j.envint.2019.105220CrossRefPubMed

27.

Yang W, Ling X, He S et al (2023) PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per-and polyfluoroalkyl substances: an integrated approach. Environ Int 178:108138. https://doi.org/10.1016/j.envint.2023.108138CrossRefPubMed

28.

Lee SH, Tseng WC, Du ZY et al (2021) Lipid responses to environmental perfluoroalkyl substance exposure in a Taiwanese Child cohort. Environ Pollut 283:117007CrossRefPubMed

29.

Marques E, Pfohl M, Wei W et al (2022) Replacement per- and polyfluoroalkyl substances (PFAS) are potent modulators of lipogenic and drug metabolizing gene expression signatures in primary human hepatocytes. Toxicol Appl Pharmacol 442:115991. https://doi.org/10.1016/j.taap.2022.115991CrossRefPubMedPubMedCentral

30.

Huck I, Beggs K, Apte U (2018) Paradoxical protective effect of perfluorooctanesulfonic acid against high-fat diet-induced hepatic steatosis in mice. Int J Toxicol 37:383–392. https://doi.org/10.1177/1091581818790934CrossRefPubMedPubMedCentral

31.

Wang Y, Aimuzi R, Nian M, Zhang Y, Luo K, Zhang J (2021) Perfluoroalkyl substances and sex hormones in postmenopausal women: NHANES 2013–2016. Environ Int 149:106408. https://doi.org/10.1016/j.envint.2021.106408CrossRefPubMed

32.

Wen X, Wang M, Xu X, Li T (2022) Exposure to per- and polyfluoroalkyl substances and mortality in US adults: a population-based cohort study. Environ Health Perspect 130:67007. https://doi.org/10.1289/ehp10393CrossRefPubMed

33.

Siddiqui MS, Vuppalanchi R, Van Natta ML et al (2019) Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol: Off Clin Practice J Am Gastroenterol Assoc 17:156–63.e2. https://doi.org/10.1016/j.cgh.2018.04.043CrossRef

34.

Jiang W, Huang S, Teng H et al (2018) Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 8:e021787. https://doi.org/10.1136/bmjopen-2018-021787CrossRefPubMedPubMedCentral

35.

Tang A, Cloutier G, Szeverenyi NM, Sirlin CB (2015) Ultrasound elastography and MR elastography for assessing liver fibrosis: part 2, diagnostic performance, confounders, and future directions. AJR Am J Roentgenol 205:33–40. https://doi.org/10.2214/ajr.15.14553CrossRefPubMedPubMedCentral

36.

Tang A, Cloutier G, Szeverenyi NM, Sirlin CB (2015) Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques. AJR Am J Roentgenol 205:22–32. https://doi.org/10.2214/ajr.15.14552CrossRefPubMedPubMedCentral

37.

Kim D, Cholankeril G, Loomba R, Ahmed A (2021) Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017–2018. Clin Gastroenterol Hepatol: Off Clin Practice J Am Gastroenterol Assoc 19:1499–501.e2. https://doi.org/10.1016/j.cgh.2020.08.017CrossRef

38.

Benowitz NL (1996) Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 18:188–204. https://doi.org/10.1093/oxfordjournals.epirev.a017925CrossRefPubMed

39.

Mamsen LS, Jönsson BAG, Lindh CH et al (2017) Concentration of perfluorinated compounds and cotinine in human foetal organs, placenta, and maternal plasma. Sci Total Environ 596–597:97–105. https://doi.org/10.1016/j.scitotenv.2017.04.058CrossRefPubMed

40.

Limei E, Zhang S, Jiang X (2023) Association between perfluoroalkyl substances exposure and the prevalence of nonalcoholic fatty liver disease in the different sexes: a study from the National Health and Nutrition Examination Survey 2005–2018. Environ Sci Pollut Res Int 30:44292–44303. https://doi.org/10.1007/s11356-023-25258-4CrossRef

41.

Wu Z, Ouyang T, Liu H, Cao L, Chen W (2023) Perfluoroalkyl substance (PFAS) exposure and risk of nonalcoholic fatty liver disease in the elderly: results from NHANES 2003–2014. Environ Sci Pollut Res Int 30:64342–64351. https://doi.org/10.1007/s11356-023-26941-2CrossRefPubMed

42.

Goosey E, Harrad S (2011) Perfluoroalkyl compounds in dust from Asian, Australian, European, and North American homes and UK cars, classrooms, and offices. Environ Int 37:86–92. https://doi.org/10.1016/j.envint.2010.08.001CrossRefPubMed

43.

Wen Y, Chen J, Li J, Arif W, Kalsotra A, Irudayaraj J (2020) Effect of PFOA on DNA methylation and alternative splicing in mouse liver. Toxicol Lett 329:38–46. https://doi.org/10.1016/j.toxlet.2020.04.012CrossRefPubMedPubMedCentral

44.

Rashid F, Ramakrishnan A, Fields C, Irudayaraj J (2020) Acute PFOA exposure promotes epigenomic alterations in mouse kidney tissues. Toxicol Rep 7:125–132. https://doi.org/10.1016/j.toxrep.2019.12.010CrossRefPubMedPubMedCentral

45.

Xu M, Wan J, Niu Q, Liu R (2019) PFOA and PFOS interact with superoxide dismutase and induce cytotoxicity in mouse primary hepatocytes: a combined cellular and molecular methods. Environ Res 175:63–70. https://doi.org/10.1016/j.envres.2019.05.008CrossRefPubMed

46.

Lin CY, Lin LY, Chiang CK et al (2010) Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol 105:1354–1363. https://doi.org/10.1038/ajg.2009.707CrossRefPubMed

47.

Steenland K, Fletcher T, Stein CR et al (2020) Review: evolution of evidence on PFOA and health following the assessments of the C8 science panel. Environ Int 145:106125. https://doi.org/10.1016/j.envint.2020.106125CrossRefPubMed

48.

Perkins RG, Butenhoff JL, Kennedy GL Jr, Palazzolo MJ (2004) 13-week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug Chem Toxicol 27:361–378. https://doi.org/10.1081/dct-200039773CrossRefPubMed

49.

Liang W, Menke AL, Driessen A et al (2014) Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS ONE 9:e115922. https://doi.org/10.1371/journal.pone.0115922CrossRefPubMedPubMedCentral

50.

Di Nisio A, Rocca MS, De Toni L et al (2020) Endocrine disruption of vitamin D activity by perfluoro-octanoic acid (PFOA). Sci Rep 10:16789. https://doi.org/10.1038/s41598-020-74026-8CrossRefPubMedPubMedCentral

51.

Jahn D, Dorbath D, Kircher S et al (2019) Beneficial effects of vitamin D treatment in an obese mouse model of non-alcoholic steatohepatitis. Nutrients. https://doi.org/10.3390/nu11010077CrossRefPubMedPubMedCentral

52.

Park SK, Wang X, Ding N et al (2022) Per- and polyfluoroalkyl substances and incident diabetes in midlife women: the Study of Women’s Health Across the Nation (SWAN). Diabetologia 65:1157–1168. https://doi.org/10.1007/s00125-022-05695-5CrossRefPubMedPubMedCentral

53.

Pan K, Xu J, Long X, Yang L, Huang Z, Yu J (2023) The relationship between perfluoroalkyl substances and hypertension: a systematic review and meta-analysis. Environ Res 232:116362. https://doi.org/10.1016/j.envres.2023.116362CrossRefPubMed

54.

Liu B, Zhu L, Wang M, Sun Q (2023) Associations between Per-and polyfluoroalkyl substances exposures and blood lipid levels among adults-a meta-analysis. Environ Health Perspect 131:56001. https://doi.org/10.1289/ehp11840CrossRefPubMed

55.

Behr AC, Plinsch C, Braeuning A, Buhrke T (2020) Activation of human nuclear receptors by perfluoroalkylated substances (PFAS). Toxicol In Vitro :Int J Publ Assoc BIBRA 62:104700. https://doi.org/10.1016/j.tiv.2019.104700CrossRef

56.

Kowalska D, Sosnowska A, Bulawska N et al (2023) How the structure of per-and polyfluoroalkyl substances (PFAS) influences their binding potency to the peroxisome proliferator-activated and thyroid hormone receptors-an in silico screening study. Molecules. https://doi.org/10.3390/molecules28020479CrossRefPubMedPubMedCentral

57.

Matilla-Santander N, Valvi D, Lopez-Espinosa MJ et al (2017) Exposure to perfluoroalkyl substances and metabolic outcomes in pregnant women: evidence from the spanish inma birth cohorts. Environ Health Perspect 125:117004. https://doi.org/10.1289/ehp1062CrossRefPubMedPubMedCentral

58.

Xu M, Legradi J, Leonards P (2022) Using comprehensive lipid profiling to study effects of PFHxS during different stages of early zebrafish development. Sci Total Environ 808:151739. https://doi.org/10.1016/j.scitotenv.2021.151739CrossRefPubMed

59.

Bassler J, Ducatman A, Elliott M et al (2019) Environmental perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis and altered serum adipocytokines. Environ Pollut 247:1055–1063. https://doi.org/10.1016/j.envpol.2019.01.064CrossRefPubMedPubMedCentral

60.

Shao W, Xu J, Xu C et al (2021) Early-life perfluorooctanoic acid exposure induces obesity in male offspring and the intervention role of chlorogenic acid. Environ Pollut 272:115974. https://doi.org/10.1016/j.envpol.2020.115974CrossRefPubMed

61.

Pfohl M, Ingram L, Marques E et al (2020) Perfluorooctanesulfonic acid and perfluorohexanesulfonic acid alter the blood lipidome and the hepatic proteome in a murine model of diet-induced obesity. Toxicol Sci 178:311–324. https://doi.org/10.1093/toxsci/kfaa148CrossRefPubMedPubMedCentral

62.

Dhir RN, Dworakowski W, Thangavel C, Shapiro BH (2006) Sexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormone. J Pharmacol Exp Ther 316:87–94. https://doi.org/10.1124/jpet.105.093773CrossRefPubMed

63.

Klair JS, Yang JD, Abdelmalek MF et al (2016) A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 64:85–91. https://doi.org/10.1002/hep.28514CrossRefPubMed

64.

Roth K, Yang Z, Agarwal M et al (2021) Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury. Environ Int 157:106843. https://doi.org/10.1016/j.envint.2021.106843CrossRefPubMedPubMedCentral

65.

Schillemans T, Iszatt N, Remy S et al (2023) Cross-sectional associations between exposure to per- and polyfluoroalkyl substances and body mass index among European teenagers in the HBM4EU aligned studies. Environ Pollut 316:120566. https://doi.org/10.1016/j.envpol.2022.120566CrossRefPubMed

66.

Stratakis N, Rock S, La Merrill MA et al (2022) Prenatal exposure to persistent organic pollutants and childhood obesity: a systematic review and meta-analysis of human studies. Obes Rev: off J Int Assoc Study Obes 23(Suppl 1):e13383. https://doi.org/10.1111/obr.13383CrossRef

67.

Cheng W, Li M, Zhang L et al (2023) Close association of PFASs exposure with hepatic fibrosis than steatosis: evidences from NHANES 2017–2018. Ann Med 55:2216943. https://doi.org/10.1080/07853890.2023.2216943CrossRefPubMedPubMedCentral

Titel: Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018
verfasst von: Yuxiao Zhang
Min Zhang
Shanjiamei Jiang
Heng Hu
Xinzhi Wang
Fan Yu
Yue’e Huang
Yali Liang
Publikationsdatum: 19.05.2024
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-024-01865-5

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018

Abstract

Objectives

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie